AI Bias Analysis
4 models · Takes ~15 seconds
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
Source
Stat News
Opens original article in a new tab
(MedPage Today) -- NEW ORLEANS -- Treatment with survodutide led to significant weight loss and reductions in liver fat in phase III trials of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), but about a fifth of...
(MedPage Today) -- Two more cases of the New World screwworm have been confirmed, including one outside the main cluster in Texas, demonstrating the difficulty of stopping a pest that could potentially devastate the nation's cattle industry, the...
(MedPage Today) -- For U.S. kids born after the rotavirus vaccine was introduced, recommendations against administration in the neonatal intensive care unit (NICU) appeared to be a strong barrier to getting immunized, researchers reported. Children...
Health workers at the epicenter of Congo's Ebola outbreak are laboring with little pay or rest.
